Laboratory variables Sample Clauses

Laboratory variables. These laboratory variables are recorded as positive if keywords are present in the medical record or progress note. (Data abstracted directly from laboratory reports is described in a later section.)
AutoNDA by SimpleDocs
Laboratory variables. Blood and urine samples for determination of haematology, clinical chemistry, and urinalysis will be collected as outlined in CSP section 6.4.5. Laboratory values will be graded according to CTCAE version 4.0. Neutrophils and glucose values with a grade >= 4 will be used to determine tolerability for the go-no go criteria. The baseline value of each laboratory variable will be derived, as described in the Clinical Study Protocol; values captured up to 3 days before baseline visit will be considered suitable for a baseline value. If multiple records are present between -3 days and baseline visit (cycle 1 day 1) then the last value obtained prior to the first dose of study medication will be considered as baseline. Alternatively, if two visits are equally eligible to assess patient status at baseline (e.g., screening and baseline assessments both prior to first dose with no washout or other intervention in the screening period), the average can be taken as a baseline value. The post-baseline non-missing values of laboratory parameter closest to the scheduled visit date will be considered as the visit value. If two assessments are equidistant from a scheduled visit, then the earlier of the two will be used. The visit will be missing if no assessment was reported within the specified visit window around the scheduled date. Designation of visits for Lab data assessment are given in table below (Table 7): Cycle No. Visit day Target day Day Range Screening -1 -28 – -1 1 Day 1 (Baseline) 1 -3 – 1 (prior to dose) 1 Day 2 2 2 – 3 1 Day 5 5 4 – 7 1 Day 9 9 8 – 12 1 Day 16 16 13 – 19 1 Day 23 23 20 – 26 2 Day 2 30 27 – 33 2 Day 8 36 34 – 39 2 Day 15 43 40 – 46 2 Day 22 50 47 – 54 3 Day 2 58 55 – 72 4 Day 2 86 73 – 100 Y Day 1 X X-13 – X+14 Where Y = 5, 6 and X = (Y-1)*28+1 Cycle No. Visit day Target day Day Range Screening -1 -28 – -1 1 Day 1 (Baseline) 1 -3 – 1 (prior to dose) 1 Day 2 2 2 – 3 1 Day 5 5 4 – 7 1 Day 9 9 8 – 12 1 Day 16 16 13 – 19 1 Day 23 23 20 – 26 2 Day 2 30 27 – 44 3 Day 2 58 45 – 71 Y Day 2 X X-13 – X+14 Where Y = 5, 6 and X = (Y-1)*28+1

Related to Laboratory variables

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Laboratory a. Drug tests shall be conducted by laboratories licensed and approved by SAMSHA which comply with the American Occupational Medical Association (AOMA) ethical standards. Upon advance notice, the parties retain the right to inspect the laboratory to determine conformity with the standards described in this policy. The laboratory will only test for drugs identified in this policy. The City shall bear the cost of all required testing unless otherwise specified herein. b. Tests for all controlled substances, except alcohol, shall be by oral fluid testing and shall consist of two procedures, a screen test and, if that is positive, a confirmation test. c. To be considered positive for reporting by the laboratory to the City, both samples must be tested separately in separate batches and must also show positive results on the confirmatory test. d. In the event of a positive test, the testing laboratory will perform an automatic confirmation test on the original specimen at no cost to the Covered Employee. In addition, the testing laboratory shall preserve a sufficient specimen to permit an independent re-testing at the Covered Employee’s request and expense. The same, or any other, approved laboratory may conduct re-tests. The laboratory shall endeavor to notify the designated MRO of positive drug, alcohol, or adulterant tests results within five (5) working days after receipt of the specimen.

  • Laboratory Services Covered Services include prescribed diagnostic clinical and anatomic pathological laboratory services and materials when authorized by a Member's PCP and HPN’s Managed Care Program.

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order. (b) The technical evaluation committee may call the responsive bidders for discussion or presentation to facilitate and assess their understanding of the scope of work and its execution. However, the committee shall have sole discretion to call for discussion / presentation. (c) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled. (d) AIIMS Jodhpur shall have right to accept or reject any or all tenders without assigning any reasons thereof.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Curriculum Development This includes the analysis and coordination of textual materials; constant review of current literature in the field, some of which are selected for the college library collection, the preparation of selective, descriptive materials such as outlines and syllabi; conferring with other faculty and administration on curricular problems; and, the attendance and participation in inter and intra-college conferences and advisory committees.

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Technology Upgrades Notwithstanding any other provision of this Agreement, Verizon shall have the right to deploy, upgrade, migrate and maintain its network at its discretion. The Parties acknowledge that Verizon, at its election, may deploy fiber throughout its network and that such fiber deployment may inhibit or facilitate PNG’s ability to provide service using certain technologies. Nothing in this Agreement shall limit Verizon's ability to modify its network through the incorporation of new equipment or software or otherwise. PNG shall be solely responsible for the cost and activities associated with accommodating such changes in its own network.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

  • Commercial Operation Date Testing and Modifications Prior to the Commercial Operation Date, the Connecting Transmission Owner shall test the Connecting Transmission Owner’s Attachment Facilities and System Upgrade Facilities and System Deliverability Upgrades and Developer shall test the Large Generating Facility and the Developer Attachment Facilities to ensure their safe and reliable operation. Similar testing may be required after initial operation. Developer and Connecting Transmission Owner shall each make any modifications to its facilities that are found to be necessary as a result of such testing. Developer shall bear the cost of all such testing and modifications. Developer shall generate test energy at the Large Generating Facility only if it has arranged for the injection of such test energy in accordance with NYISO procedures.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!